Sarepta's Eteplirsen Review Delay Emboldens Duchenne Community

Is the lack of rejection cause for optimism, or will eteplirsen end up like BioMarin's drisapersen?

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America